Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-04-19
2011-11-29
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388230, C530S391100, C530S391700, C424S133100, C424S141100, C424S178100, C424S183100
Reexamination Certificate
active
08067546
ABSTRACT:
Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
REFERENCES:
patent: 5573924 (1996-11-01), Beckmann et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 7261892 (2007-08-01), Terrett et al.
patent: 7498298 (2009-03-01), Doronina et al.
patent: 7659241 (2010-02-01), Senter et al.
patent: 7662387 (2010-02-01), Law et al.
patent: 7829531 (2010-11-01), Senter et al.
patent: 7851437 (2010-12-01), Senter et al.
patent: 2003/0083263 (2003-05-01), Doronina et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2004/0131612 (2004-07-01), Watkins et al.
patent: 2004/0157782 (2004-08-01), Doronina et al.
patent: 2005/0106644 (2005-05-01), Cairns et al.
patent: 2005/0113308 (2005-05-01), Senter et al.
patent: 2005/0118656 (2005-06-01), Terrett
patent: 2005/0123547 (2005-06-01), Terrett
patent: 2005/0191299 (2005-09-01), Swamy et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0083736 (2006-04-01), Law et al.
patent: 2006/0233794 (2006-10-01), Law et al.
patent: 2007/0292422 (2007-12-01), Law et al.
patent: 2008/0025989 (2008-01-01), Law et al.
patent: 2008/0138341 (2008-06-01), Law et al.
patent: 2008/0138343 (2008-06-01), Law et al.
patent: 2008/0226657 (2008-09-01), Doronina et al.
patent: 2008/0248051 (2008-10-01), Doronina et al.
patent: 2008/0248053 (2008-10-01), Doronina et al.
patent: 2009/0047296 (2009-02-01), Doronina et al.
patent: 2009/0074772 (2009-03-01), Law et al.
patent: 2010/0129362 (2010-05-01), Law et al.
patent: 2010/0150925 (2010-06-01), Law et al.
patent: 2010/0158910 (2010-06-01), Law et al.
patent: 2010/0183636 (2010-07-01), Law et al.
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/088172 (2002-11-01), None
patent: WO 03/026577 (2003-04-01), None
patent: WO 03/046581 (2003-06-01), None
patent: WO 2004/010957 (2004-02-01), None
patent: WO 2004/073656 (2004-09-01), None
patent: WO 2004/073656 (2004-09-01), None
patent: WO 2005/081711 (2005-09-01), None
patent: WO 2006/044643 (2006-04-01), None
patent: WO 2006/113909 (2006-10-01), None
patent: WO 2007/038637 (2007-04-01), None
patent: WO 2008/074004 (2008-06-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Adam, et al. “CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding”British J. of Cancer. 95:298-306 (2006).
U.S. Appl. No. 11/833,954, Doronina et al.
U.S. Appl. No. 12/265,451, Law et al.
Law et al., “Anti-CD70 Antibody Drug Conjugates Mediate Renal Carcinoma Cell Killing Through Cytotoxic Drug Delivery and Antibody-Dependent Cellular Cytotoxicity (abstract only)”Proc Amer Assoc Cancer Res. 46:6143 (2005).
McEarchern et al., “Engineered Anti-CD70 Antibody Variants Support Multiple Effector Functions and Exhibit Potent in Vitro and in Vivo Antitumor Activities (abstract only)”Proc Amer Assoc Cancer Res. 46:6142 (2005).
McEarchern, Julie, “Antitumor Activities of Engineered Anti-CD70 Antibody (h1F6)”Presentation by Seattle Genetics at Annual Meeting of American Association for Cancer ResearchApr. 16-20:1-15 (2005).
Oflazoglu et al.“ in Vivo Characterization of the Mechanism of Action of c1F6, an Anti-CD70 Antibody,” Abstract No. 3732, 97th Annual Meeting of the American Association for Cancer Research, Apr. 1-5, 2006, Washington, D.C.
PCT Search Report of Oct. 4, 2007 for application PCT/US2006/037753 (WO 2007/038637 A3).
PCT Search Report of Dec. 4, 2008 for application PCT/US2007/087401 (WO 2008/074004 A3).
PCT Search Report of Dec. 22, 2004 for application PCT/US04/05247 (Wo 2004/073656 A3) (Corrected Version).
Reff, M. et al., “Future of Monoclonal Antibodies in the Treatment of Hematologic Malignancies ”Cancer Control. 9(2):152-166 (2002).
U.S. Appl. No. 10/546,304 Amendment filed Nov. 21, 2008 in response to Final Office Action mailed May 22, 2008.
U.S. Appl. No. 10/546,304 Final Office Action mailed May 22, 2008.
Agathanggelou et al., “Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells,”Am J. Pathol., 147(4):1152-1160 (1995).
Agematsu et al., “Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction,”Blood, 91(1):173-180 (1998).
Agematsu et al., “B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production,”Eur. J. Immunol., 27(8):2073-2079 (1997).
Akiba et al., “Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis,”J. Exp. Med., 191(2):375-380 (2000).
Baert, et al., “Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crogn's Disease,”N. Engl. J. Med., 348(7):601-608 (2003).
Bahler et al., “Clonal evolution of a follicular lymphoma: evidence for antigen selection,”PNAS, 89(15):6770-6774 (Aug. 1992).
Bahler et al., “Antigen Selection in Human Lymphomagenesis,”Cancer Res., 52(19 Suppl.):5547s-5551s (Oct. 1, 1992).
Bowman et al., “The Cloning of CD70 and Its Identification as the Ligand for CD27,”J. Immunol., 152(4)1756-1761 (1994).
Brugnoni et al., “CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation,”Immunol. Lett., 55(2):99-104 (1997).
Carter, P., “Improving the Efficacy of Antibody-Based Cancer Therapies,”Nature Reviews, (1):118-129 (Nov. 2001).
Casset, et al., “A peptide mimetic of an anti-CD4 monoclonal antibody of rational design,”Biochem, Biophys. Res., 307:198-205 (2003).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,”J. Mol. Biol., 5:293(4):865-881 (1999).
Colman, PM., “Effects of aminio acid sequence changes on antibody-antigen interactions,”Res. Immunology, 145:33-36 (1994).
De Jong et al., “Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors,”J. Immunol., 146(8):2488-2494 (Apr. 15, 1991).
Den Haan et al., “Identification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility Antigen,”Science, 268(5216):1476-1480 (1995).
De Pascalis et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential of Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,”J. Immunol. 15/169(6):3076-84 (2002).
Dillman, R. O., “Monoclonal Antibodies for Treating Cancer”,Ann. Int. Med., 111:592-603 (Oct. 1989).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,”Nature Biotechnology, 21(7):778-784 (Jul. 2003) + erratum: 21(8):941 (Aug. 2003).
Emery, et al., “Humanised monoclonal antibodies for therapeutic applications,”Exp. Opin. Invest. Drugs, 3(3):241-251 (1994).
European Search Report of Mar. 12, 2007 for European Application EP 04 71 3441.
Giralt et al., “Leukem
Carter Paul
Law Che-Leung
McDonagh Charlotte
McEarchern Julie
Alston & Bird LLP
Gussow Anne M.
Seattle Genetics Inc.
LandOfFree
Humanized anti-CD70 binding agents and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-CD70 binding agents and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-CD70 binding agents and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4307132